Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Darifenacin Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,535Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Darifenacin hbr, 133099-07-7, Emselex, Darifenacin (hydrobromide), Darifenacin hydrobromide [usan], Cr02eyq8gv
    Molecular Formula
    C28H31BrN2O2
    Molecular Weight
    507.5  g/mol
    InChI Key
    UQAVIASOPREUIT-VQIWEWKSSA-N
    FDA UNII
    CR02EYQ8GV
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
    2.1.2 InChI
    InChI=1S/C28H30N2O2.BrH/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26;/h1-12,19,25H,13-18,20H2,(H2,29,31);1H/t25-;/m1./s1
    2.1.3 InChI Key
    UQAVIASOPREUIT-VQIWEWKSSA-N
    2.1.4 Canonical SMILES
    C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br
    2.1.5 Isomeric SMILES
    C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br
    2.2 Other Identifiers
    2.2.1 UNII
    CR02EYQ8GV
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (s)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide

    2. Darifenacin

    3. Darifenacin Hydrochloride

    4. Darifenacine

    5. Darifenicin

    6. Emselex

    7. Enablex

    8. Uk-88525

    2.3.2 Depositor-Supplied Synonyms

    1. Darifenacin Hbr

    2. 133099-07-7

    3. Emselex

    4. Darifenacin (hydrobromide)

    5. Darifenacin Hydrobromide [usan]

    6. Cr02eyq8gv

    7. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide Hydrobromide

    8. Uk-88525-04 (hydrobromide)

    9. Chebi:31455

    10. Uk-88525-04 (hbr)

    11. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide Hydrobromide

    12. 133099-07-7 (hbr)

    13. Dsstox_cid_26780

    14. Dsstox_rid_81899

    15. Dsstox_gsid_46780

    16. (s)-2-{1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl}-2,2-diphenylacetamide Hydrobromide

    17. Uk-88525

    18. Darilong

    19. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide

    20. Uk 88525-04 Hydrobromide

    21. Cas-133099-07-7

    22. Ncgc00168775-01

    23. Unii-cr02eyq8gv

    24. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hydrobromide

    25. 2-{(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide Hydrobromide

    26. Enablex (tn)

    27. Darifenacinhydrobromide

    28. Diphenyl-acetamide Hydrobromide

    29. Darifenacin Hydrobromide- Bio-x

    30. Chembl1200935

    31. Dtxsid9046780

    32. Hy-a0012

    33. Tox21_112636

    34. Darifenacin Hydrobromide (jan/usan)

    35. Darifenacin Hydrobromide [mi]

    36. Mfcd08141803

    37. S3144

    38. Darifenacin Hydrobromide [jan]

    39. Akos015969311

    40. Tox21_112636_1

    41. Ac-1894

    42. Ccg-220969

    43. Cs-0380

    44. Darifenacin Hydrobromide [mart.]

    45. Darifenacin Hydrobromide [usp-rs]

    46. Darifenacin Hydrobromide [who-dd]

    47. Ncgc00263922-02

    48. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (3s)-

    49. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (s)-

    50. 3-pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-alpha,alpha-diphenyl-, Hydrobromide (1:1), (3s)-

    51. As-35087

    52. Bd164350

    53. Darifenacin Hydrobromide [ema Epar]

    54. Darifenacin Hydrobromide, >=98% (hplc)

    55. Sw219426-1

    56. Darifenacin Hydrobromide [orange Book]

    57. Uk-88525-04

    58. D01699

    59. Q-101006

    60. Q27114313

    61. Z1691545283

    62. Darifenacin Hydrobromide, United States Pharmacopeia (usp) Reference Standard

    63. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hbr

    64. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohbr, (3s)-

    65. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohydrobromide, (3s)-

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 507.5 g/mol
    Molecular Formula C28H31BrN2O2
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count7
    Exact Mass506.15689 g/mol
    Monoisotopic Mass506.15689 g/mol
    Topological Polar Surface Area55.6 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity607
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameDarifenacin hydrobromide
    Active IngredientDarifenacin hydrobromide
    Dosage FormTablet, extended release
    Routeoral
    Strength7.5mg; 15mg
    Market StatusTentative Approval
    CompanyAnchen Pharms

    2 of 4  
    Drug NameEnablex
    PubMed HealthDarifenacin (By mouth)
    Drug ClassesUrinary Antispasmodic
    Drug LabelENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[...
    Active IngredientDarifenacin hydrobromide
    Dosage FormTablet, extended release
    RouteOral
    Strengtheq 15mg base; eq 7.5mg base
    Market StatusPrescription
    CompanyWarner Chilcott

    3 of 4  
    Drug NameDarifenacin hydrobromide
    Active IngredientDarifenacin hydrobromide
    Dosage FormTablet, extended release
    Routeoral
    Strength7.5mg; 15mg
    Market StatusTentative Approval
    CompanyAnchen Pharms

    4 of 4  
    Drug NameEnablex
    PubMed HealthDarifenacin (By mouth)
    Drug ClassesUrinary Antispasmodic
    Drug LabelENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[...
    Active IngredientDarifenacin hydrobromide
    Dosage FormTablet, extended release
    RouteOral
    Strengtheq 15mg base; eq 7.5mg base
    Market StatusPrescription
    CompanyWarner Chilcott

    4.2 Drug Indication

    Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Muscarinic Antagonists

    Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)

    Urological Agents

    Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Cholinergic Muscarinic Antagonists [MoA]; Cholinergic Muscarinic Antagonist [EPC]
    5.3 ATC Code

    G04BD10